{
    "2020-06-07": [
        [
            {
                "time": "",
                "original_text": "中国大陆已有6种疫苗在临床试验 疫苗板块或迎上涨",
                "features": {
                    "keywords": [
                        "疫苗",
                        "临床试验",
                        "疫苗板块",
                        "上涨"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "研值担当，价值护航！第14届上市公司价值评选评委阵容亮相！申报系统开放",
                "features": {
                    "keywords": [
                        "上市公司",
                        "价值评选",
                        "评委阵容",
                        "申报系统"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "【民生医药|周报】：疫苗集中采购政策对疫苗价格和量影响很有限，持续关注后疫情时代下“枢纽性”和内需驱动型板块的成长确定性",
                "features": {
                    "keywords": [
                        "疫苗",
                        "集中采购",
                        "政策",
                        "价格",
                        "量",
                        "后疫情时代",
                        "枢纽性",
                        "内需驱动",
                        "成长确定性"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【药咖君】罕见肺部疾病首款疗法获批；56亿销售额，石药王牌迎来首个对手；豪森拿下首仿；BI、武田、正大天晴、绿叶",
                "features": {
                    "keywords": [
                        "罕见病",
                        "肺部疾病",
                        "疗法获批",
                        "石药",
                        "销售额",
                        "首仿",
                        "BI",
                        "武田",
                        "正大天晴",
                        "绿叶"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}